NCT07267728

Brief Summary

This is a single-group, virtual clinical trial evaluating the effects of a daily dietary supplement (DITTO Cycle Supplement) on menstrual cycle symptoms across three menstrual cycles. The study investigates changes in symptom severity through validated questionnaires including the Menstrual Symptoms Questionnaire (MSQ), and proportion of participants experiencing symptom reduction.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

November 19, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 5, 2025

Completed
Last Updated

August 17, 2026

Status Verified

August 1, 2026

Enrollment Period

5 months

First QC Date

November 19, 2025

Last Update Submit

August 14, 2026

Conditions

Keywords

BloatingMood Disorders

Outcome Measures

Primary Outcomes (1)

  • Change in Menstrual Symptoms Questionnaire (MSQ) Scores

    Change from baseline in menstrual symptom severity as measured by the validated 24-item Menstrual Symptoms Questionnaire (MSQ). Rated on a 5-point Likert scale (Never, Rarely, Sometimes, Often, Always). Higher scores indicate greater symptom severity.

    Baseline, Menstrual Cycle 1, Menstrual Cycle 2, Menstrual Cycle 3 (each measured 2 days following menstruation)

Secondary Outcomes (2)

  • Symptom Severity Ratings

    Baseline, Menstrual Cycle 1, Menstrual Cycle 2, Menstrual Cycle 3 (each measured 2 days following menstruation)

  • Proportion of participants with perceived reduction in menstrual cycle symptoms

    Baseline, Menstrual Cycle 1, Menstrual Cycle 2, Menstrual Cycle 3 (each measured 2 days following menstruation)

Study Arms (1)

DITTO Cycle Supplement

EXPERIMENTAL

Participants will take two capsules of the DITTO Cycle Supplement once daily, starting two days after menstrual bleeding ends, for the duration of three menstrual cycles.

Dietary Supplement: DITTO Cycle Supplement

Interventions

DITTO Cycle SupplementDIETARY_SUPPLEMENT

The capsules contain 10 evidence-based ingredients (8 nutrients, 2 extracts) for premenstrual symptoms and period pain. Ingredients are as follows: saffron extract, chamomile oil, vitamin D3 oil, omega 3 DHA and EPA fatty acids (algal oil), iron, zinc, vitamin B6, chromium, vitamin C, magnesium. Capsules should be taken in the morning with the first meal and a glass of water. Capsules are designed with a nutrient delivery biotechnology "beadlet-in-oil).

DITTO Cycle Supplement

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Female-at-birth, generally healthy
  • Aged 18-45
  • In the last three menstrual cycles, has experienced three or more of the following symptoms associated with their menstrual cycle: Menstrual cramps, Bloating, Breast tenderness, Headaches, Fatigue, Muscle aches and/or joint pain, Cravings, Mood swings, Low mood, Feelings of anxiety, Irritability, Difficulty concentrating
  • Natural menstrual cycle or regular withdrawal bleeds if on hormonal contraception
  • Has a regular menstrual cycle length, between 21 and 35 days
  • Tracks their menstrual cycle and can predict their period dates
  • Willing to comply with study requirements
  • Willing to refrain from taking any other products, medications, or supplements that target menstrual health during the test period
  • No known allergies to the ingredients listed in the product

You may not qualify if:

  • Anyone diagnosed with chronic conditions that may affect study outcome (e.g. heart conditions, diabetes, endocrine-related disorders, reproductive health-related cancers)
  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
  • Women who are pregnant, breastfeeding, or trying to conceive
  • Anyone unwilling to follow the study protocol
  • Anyone in perimenopause, menopause, or experiencing menopausal-type symptoms
  • Started, changed, or stopped taking hormonal birth control in the last three months
  • Anyone with planned surgery during the study period
  • Anyone with a history of substance abuse
  • Anyone currently participating or planning to participate in a research study
  • Has a planned insertion or replacement of an IUD in the next 12 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Citruslabs

Las Vegas, Nevada, 89118, United States

Location

MeSH Terms

Conditions

Premenstrual SyndromeDysmenorrheaMood Disorders

Condition Hierarchy (Ancestors)

Menstruation DisturbancesPathologic ProcessesPathological Conditions, Signs and SymptomsPelvic PainPainNeurologic ManifestationsSigns and SymptomsMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 19, 2025

First Posted

December 5, 2025

Study Start

February 1, 2025

Primary Completion

July 1, 2025

Study Completion

July 1, 2025

Last Updated

August 17, 2026

Record last verified: 2026-08

Locations